NOTE:  Any and/or all workshop syllabus materials on this website are for the exclusive use of the faculty and participants of the workshop.  Any copying, duplicating or reproducing of any and/or all workshop syllabus materials by electronic, mechanical or other means for any purpose other than this workshop is strictly prohibited without prior written consent of the author of those workshop syllabus materials.

7.25 - 7.30 am      Welcome & opening remarksBanke Agarwal, MD

7.30 – 9.15 am      Session I

Screening, surveillance and endoscopic therapy for colon cancer
Moderators: Steven Fern, DO & David Cort, MD

Screening and endoscopic therapy for colon cancer

Screening colonoscopyDavid Lieberman, MD

      • For whom, when and how often
      • Data on potential benefit of screening colonoscopy
      • Should screening be started earlier in some high risk groups
      • Screening in the elderly: is screening is really beneficial
      • Impact of screening colonoscopy on right and left sided colonic tumors

        View Presentation

CT colonography: Are we dealing with the inevitableJoel Brill, MD

  • Issues/factors favoring use of CT colonography
  • Why CMS did not cover CT colonography
  • Cost of CT colonography vs. colonoscopy
  • Will gastroenterologists ever be reimbursed for interpreting CT colonography
  • Potential partnerships between radiologists and gastroenterologists for developing centers for colon cancer screening

    View Presentation

Molecular markers for colon cancer screeningSteven Itzkowitz, MD

  • Anticipated role of molecular markers in colon cancer screening and diagnosis
  • Are there any markers available for use in near future
  • Could the development of molecular markers lead to more efficient and cost-effective screening programs
  • What kind of validation studies are required prior to their use clinically
  • Performance characteristics acceptable for their use in colon cancer screening

    View Presentation

Endoscopic therapy of colorectal polypsDouglas Rex, MD

  • Realistic miss rate of significant polyps during colonoscopy
  • Is withdrawal time a realistic quality indicator
  • Is repeat colonoscopy ever justified for missed polyps
  • Does the data showing the reduction of colon cancer by screening colonoscopy factor in missed polyps and flat adenomas
  • What to do with diminutive polyps?
    • Remove all polyps even when they are numerous
    • Remove all right sided polyps even when they are diminutive

      View Presentation

Top »

Case discussions and Q&A – 45 mins       Download

9.15 - 9.30 am        Coffee Break

9.30 - 11.00 am      Session II

Commonly encountered neuroendocrine tumors of the gut
Moderators: Giuseppe Aliperti, MD & Steven Edmundowicz, MD

Endoscopic management of the common neuroendocrine tumors of gut –
Douglas Faigel, MD

  • Common sites where the neuroendocrine tumors are encountered in the gut
  • Pathologic types encountered in the gut and their frequency
  • Malignant potential of the NE tumors of the gut
  • Role of EUS in evaluation
  • Role of endoscopic mucosal resection
  • Follow up these patients for tumor recurrence and metastatic lesions
  • Management of recurrent gastric carcinoids in the background of atrophic gastritis

    View Presentation                    Watch Video

Evaluation and medical management of NE tumors encountered during
 endoscopy or abdominal imaging – Lowell Anthony, MD

  • Is further work-up for systemic disease needed in all patients with NE tumors of the gut
  • What kind of further evaluation is needed if the gut lesion is
    • Carcinoid tumor
    • Gastrinoma
    • Non-functioning NE tumor
  • How to evaluate patients with serum hypergastrinemia
    • What to do if no gastrin producing lesion is identifiable
    View Presentation

Surgical management of neuroendocrine tumors of the gutRichard Hodin, MD

  • Type of surgery for treatment of NE tumors
    • Gastroduodenal nodules/tumors
    • Small bowel tumors
    • Colorectal nodules/tumors
  • Role of surgery in patients  with MEN syndrome and ZE syndrome
  • Pre-operative evaluation
  • Post-operative follow up and management

    View Presentation

Case discussions and Q&A       Download

11.00 - 12.00 pm        Session III

Physicians and the law: What to do and not do when sued
Andrew Schlafly, JD and Christina McCracken, JD

View Presentation


12.00 – 12.45 pm        Lunch

12.45 -2.45 pm           Session IV

Imaging techniques in the diagnosis, staging and follow up of GI cancers
Moderators: Banke Agarwal, MD and Paul Schultz, MD

Medical Oncologist: Axel Grothey, MD
Endosonographer: Michael Kochman, MD
PET/Nuclear Medicine: Val Lowe, MD
CT/MRI: Elliott Fishman, MD

How to choose appropriate imaging techniques for pre-operative/pre-treatment staging and for post-treatment follow up of patients with

  • esophageal cancer
  • gastric cancer
  • pancreatobiliary cancer
  • colorectal cancer
  • GI stromal tumor

Principles of staging of GI cancers: Axel Grothey

  • Luminal GI Cancers
    • How does T staging and N staging affect treatment choice and in which cancers
    • What other tests help determine best treatment choices and tailor therapy
  • Pancreatobiliary cancers
    • What factors determine resectability and need for adjuvant therapy

    View Presentation

EUS and Operator dependence: Why is it important to find a good endosonographer : Michael Kochman

  • Wide range of variation between accuracy for pancreatic cancer diagnosis
    • Make sure your endosongrapher has good and on-site cytology support
  • Cost of mis-staging of luminal cancers
  • Absence of immediate feedback mechanism for a “failed” or “suboptimal” EUS exam
    • You might find out the poor results of an endosonographer only when it is too late

    View Presentation

Advances in Radiologic imaging of GI cancers: Elliot Fishman

  • Are MDCT and MRI interchangeable in use
  • CT with reconstruction vs MR Angiogram
    • How to chose
  • What is CT arterial portography and CT hepatic arteriography
    • What are their potential uses in management of GI cancers

    View Presentation

Advances in Nuclear Imaging: Val Lowe

  • Role of PET scan in
    • Staging
    • Diagnosis
  • Caveats in the use of PET scan
  • Potential benefits of PET-CT

    View Presentation

Case discussions and Q&A       Download

2.45 - 3.00 pm             Coffee break

3.00 - 4.00 pm             Session V

Ethical dilemmas in the management of patients with GI cancers
Moderators: Ira Kodner, MD and Keith Naunheim, MD

4.00 - 5.00 pm             Session VI

Surveillance and Chemoprevention of GI cancers
Moderators: Charlene Prather, MD and Michael Presti, MD

Barrett’s surveillance, chemoprevention and treatmentPrateek Sharma, MD

Top »

  • Purpose of surveillance- to diagnose early or to prevent esophageal cancers
  • How effective are current surveillance protocols
  • Cost-effectiveness of Barrett’s surveillance
  • Chemoprevention of Barrett’s-
    • Are there any agents that are currently recommended
    • Which patients would qualify
  • Treatment of Barrett’s esophagus
    • RFA vs. EMR vs. Esophagectomy
    • Whom to treat- HGD vs. LGD vs. No dysplasia
    View Presentation

Colon cancer surveillance and chemoprevention in patients with IBDWilliam Tremaine, MD

  • Risk of colon cancer in patients with IBD
  • Do UC and Crohn’s disease patients have similar risks
  • Does the risk vary with disease severity and extent
  • Does good control of IBD reduce the risk of colon cancer
  • Chemoprevention of colon cancer- are any agents currently recommended
  • Do the biologics decrease the risk of colon cancer
  • How to determine the right time for colectomy for colon cancer risk

    View Presentation

Patients with FAP and HNPCC: Surveillance and chemoprevention for colon and extracolonic cancers – Dennis Ahnen, MD

  • Prevalence of these syndromes in the general population
  • When should we consider testing for these mutations
  • Clinical features of patients with attenuated FAP and HNPCC
  • Guidelines for management of colonic polyps/colon cancer
    • role of chemoprevention
    • surveillance colonoscopy
    • surgery
  • Extracolonic tumors in these patients
    • Recommendations for surveillance of these tumor
    View Presentation

Top »

4.45 - 5.00 pm     Q&A  

5.00 pm               Conference Adjourned